Show simple item record

dc.date.accessioned2016-01-09T00:00:36Zen
dc.date.available2016-01-09T00:00:36Zen
dc.date.created2004-04-01en
dc.date.issued2004-04-01en
dc.identifier.bibliographicCitationRockville, MD: Center for Drug Evaluation and Research [CDER] 2004 April 1; [Online]. Accessed: http://www.fda.gov/cder/foi/nda/2004/21-144_Ketek_Admindocs_P1.pdf [2007 September 5]en
dc.identifier.urihttp://www.worldcat.org/search?q=ti%3AOffice%2Fdivision+memorandum+for+NDA+21-144+Ketek.&qt=advanceden
dc.identifier.urihttp://hdl.handle.net/10822/991245en
dc.languageenen
dc.publisherCenter for Drug Evaluation and Research [CDER] (United States)en
dc.sourceeweb:272053en
dc.subject.classificationSocial Control of Science and Technologyen
dc.subject.classificationDrugs and Drug Industryen
dc.titleOffice/division Memorandum for NDA 21-144 Ketek (Telithromycin)en
dc.provenanceCitation prepared by the Library and Information Services group of the Kennedy Institute of Ethics, Georgetown University for the ETHXWeb database.en
dc.provenanceCitation migrated from OpenText LiveLink Discovery Server database named EWEB hosted by the Bioethics Research Library to the DSpace collection EthxWeb hosted by DigitalGeorgetown.en


This item appears in the following Collection(s)

Show simple item record


Georgetown University Seal
©2009—2022 Bioethics Research Library
Box 571212 Washington DC 20057-1212
202.687.3885